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Abstract
non-invasive breath tests can serve as valuable diag-
nostic tools in medicine as they can determine particu-
lar enzymatic and metabolic functions in vivo. Howev-
er, methodological pitfalls have limited the actual clini-
cal application of those tests till today. a major chal-
lenge of non-invasive breath tests has remained the
provision of individually reliable test results. To over-
come  these  limitations,  a  better  understanding  of
breath kinetics during non-invasive breaths tests is es-
sential. This analysis compares the breath recovery of
a 13C-methacetin breath test with the actual serum ki-
netics of the substrate. It is shown, that breath and
serum kinetics of the same test are significantly differ-
ent over a period of 60 minutes. The recovery of the
tracer  13Co2 in breath seems to be significantly de-
layed due to intermediate storage in the bicarbonate
pool. This has to be taken into account for the appli-
cation  of  non-invasive  breath  test  protocols.  other-
wise,  breath  tests  might  display  bicarbonate  kinetics
despite the metabolic capacity of the particular target
enzyme.
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InTRodUCTIon
non-invasive breath tests (nBT) with 13C-labeled sub-
strates have been applied for the assessment of specif-
ic enzymatic/ metabolic functions and the diagnosis
of particular diseases [1, 2]. nBTs are based on in vivo
metabolism  of  certain  13C-labeled  substrates  into  a
product and  13C-labeled carbon dioxide by a specific
target enzyme. The interpretation of the test results
assumes that the appearance and recovery of  13Co2
represents the concurrent in vivo metabolism of the
substrate (fig. 1).
Expired 13Co2 can be detected by mass spectrome-
try [3], non-dispersive isotope selective infrared spec-
troscopy [4] or other methods [5]. Breath sampling can
be performed in bags or tubes [6], or by direct online
analysis [7]. Thus nBTs can determine in vivo metab-
olism without repeated blood sampling, which makes
it  more  acceptable  and  comfortable  for  both  physi-
cians and patients. However, 13Co2 is not directly ex-
haled from the target enzyme, but needs to be trans-
ported  from  the  investigated  organ  as  bicarbonate 
(H 12Co3-/H 13Co3-) into the lung [8]. Methodologi-
cal studies reported the kinetics of 13Co2 excretion al-
ready in the 1970-80ies [9-13]. It is known that emerg-
ing bicarbonate has a relatively long halftime of ap-
prox. 60 minutes [14] and that ultimately only 70% of
the emerging 13Co2 is excreted [15]. This could signifi-
cantly interfere with nBT results [8]. However, these
data did neither influence the design of later breath
test protocols nor the algorithms of nBT interpreta-
tion. different ways for calculation of test readouts
have been described in literature: some authors used
single time points (fig. 2; # 1-4) - whether at chosen
arbitrary points in time like 15, 30 or 60 minutes (fig.
2; # 2-4) [16] or maximal abundance (fig. 2; # 1) [7].
other authors applied area-under-curve analysis (fig.
2; # 5) [17, 18]. 
However, it remains somehow undefined which way
actually provides the most valid and reliable test read-
out. The aim of this analysis was to explore the corre-
lation between substrate and 13Co2 kinetics during the
intravenous 13C-methacetin breath test to improve the
analytic algorithms.
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Fig. 1. General principle of non-invasive breath tests using
13C-labeled substrates. The close connection between breath
test interpretation and in vivo metabolism is a essential pre-
condition for the validity of a test.
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The experimental study was performed in healthy vol-
unteers  after  approval  by  the  faculties  ethics  review
board. The persons were assessed by a specific breath
test using 13C-methacetin as substrate for the hepatic
cytochrome P450 1a2 system and thereby blood sam-
ples were drawn to determine the substrate kinetics.
The methodology was based on the previously report-
ed liMax test of stockmann et al. [7]. The substrate
was administered into a peripheral vein as a bolus in a
dose of 2 and 4mg/kg body weight.
BREaTH saMPlInG and analysIs
an online protocol of breath analysis was applied, to
enable a high sampling rate to enable kinetic analysis
of breath recovery. Breath samples were automatically
drawn and analyzed with a frequency of as approxi-
mately 1/min by a modified nondispersive isotope-se-
lective  infrared  spectroscopy  based  device  (fanci2-
db16,  fischer  analyseninstrumente,  leipzig,  Ger-
many). Exhaled breath was collected by a special two-
way face mask. Mean baseline 13Co2/12Co2 ratio was
recorded ten minutes before injection for the calcula-
tion of delta-over-baseline (doB) 13Co2/12Co2 ratio
values. The presented 13Co2/12Co2 ratio is standard-
ized by the Pee dee Belemnite standard [12]. for each
test, a total of 46 breath samples were automatically
analyzed. 
Blood saMPlInG and analysIs
Bloods samples were drawn from a peripheral vein be-
fore injection of the substrate, and after 30 seconds, 1,
2, 5, 10, 20, 30 and 60 minutes. samples were taken in
a standardized way. firstly, 5 ml of blood were sam-
pled and discarded. secondly, a sample of 5 ml was
taken in a serum tube for analysis. finally, the catheter
was flushed by 10 ml of 0.9% sodium chloride solu-
tion. serum probes were centrifuged with 3,000 rpm
for 4 minutes and the serum aliquot was taken into a
separate tube. Probes were analyzed for the concentra-
tion of methacetin by high performance liquid chro-
matography (HPlC). The analysis was performed by a
specialized pharmacologist, who was blinded from the
breath  test  results.  for  sample  preparation  50  ﾵl
serum  were  mixed  with  100ﾵl  of  a  acetonitrile
methanol solution (1:1) and centrifuged 14,000 rpm
for 8 minutes. finally, 10ﾵl of each sample was ap-
plied  to  the  analyzer.  a  commercial  HPlC-Test-Kit
for measurement of levetiracetam in serum (Chrom-
systems  GmbH,  Munich,  Germany)  was  used  for
analysis. The Kit-conditions were modified for estima-
tion of methacetin. Chromatography was performed
with a lC-6B system (shimadzu, duisburg, Germany)
at a flow rate of 1.5 ml/min, with Uv-detection at
260  nm.  The  sensitivity  was  0.5ﾵg/ml  with  proven
test linearity up to a concentration of 100 ﾵg/ml. The
mean inter-assay variability for methacetin was 6.8%.
REsUlTs
The pilot experiment was performed in a 34-year old
male healthy volunteer without any history of hepatic
or  extra-hepatic  disease.  His  healthy  condition  was
confirmed by routine clinical biochemistry including a
standard pattern of parameters (aspartat-aminotrans-
ferase,  alanine-aminotransferase,  bilirubin,  albumine,
creatinine, urea, blood count, prothrombin time) and a
EURoPEan JoURnal of MEdICal REsEaRCH 548 december 14, 2009
Fig.  2.  algorithms  of  test  interpretation  in  non-invasive
breath tests for calculation of the enzymatic capacity. It is
shown an exemplary plot of breath recovery (13Co2/12Co2
ratio)  after  administration  of  2  mg/kg  13C-labeled
methacetin. #1- Maximum of delta-over-baseline (doB); #2-
doB at 15 minutes; #3- doB at 30 minutes; #4- doB at 60
minutes; #5- Cumulative recovery by calculation of area un-
der doB curve.
Fig.  3.  Breath  recovery  curve  of
13Co2/12Co2 ratio  from  the  13C-
methacetin  breath  test.  13C-metha  -
cetin was applied intravenously in a
dosage of 2 and 4 mg/kg and breath
recovery  was  analyzed  for  in  total
60 minutes.
7. Lock_Umbruchvorlage  28.11.09  10:10  Seite 548standard history taking and clinical examination. The
tests were performed in a resting position on two con-
secutive days.
a baseline  13Co2/12Co2 ratio of -23.1 ﾱ 0.3 was
measured  before  injection.  The  intravenous  13C-
methacetin  injection  lead  a  rapid  increase  of  doB,
leading to the maximum of doB (doBmax) already
within 7 minutes for a dose of 2 mg/kg and 15 min-
utes for a dose of 4 mg/kg (fig. 3). The 13Co2/12Co2
ratios increased up to + 8.7 (2 mg/kg), and + 33.8 (4
mg/kg) leading to doBmax values of 31.7 (2 mg/kg),
and  57.1  (4  mg/kg),  respectively.  Consequently,  the
doB values continuously decreased slowly, leading to
13Co2/12Co2 ratios after 60min of -2.4 (doB60min
=  20.7  [2  mg/kg])  and  22.6  (doB60min  =  45.9  [4
mg/kg]) (fig. 3). 
By definition, the maximum of serum concentra-
tion of 13C-methacetin was reached directly after intra-
venous  injection  (first  sample  after  30  seconds).  a
maximum of 12.3 ﾵg/ml was determined after injec-
tion of 2 mg/kg, and maximum of 18.2 ﾵg/ml after 4
mg/kg,  respectively.  The  concentration  rapidly  de-
creased during intracorporeal distribution within few
minutes, declining down to 4.8 ﾵg/ml (2 mg/kg) and
8.0  ﾵg/ml  (4  mg/kg)  within  5  minutes.  Thereafter,
the concentration further decreased by hepatic metab-
olism  to  1.0  ﾵg/ml  (2mg/kg)  and  2.1  ﾵg/ml
(4mg/kg) at 60 minutes after injection (fig. 4).
dIsCUssIon
any protocol of breath analysis for dynamic breath
test should aim to display the actual metabolism at its
best. The literature has reported the successful differ-
entiation  between  diseased  and  non-diseased  groups
by nBTs using 13C-labeled substrates [1, 2]. However,
this is only a pre-condition for the successful imple-
mentation into clinical diagnostics. Individually reliable
test  results  that  prove  superior  prognostic  power  in
comparison to preexisting diagnostic tests are required
[19] and the different algorithms require further stan-
dardization for clinical application. If 13Co2 is not ex-
pired directly but retained inside the body during the
active metabolism, this has to be taken into account
for the methodology of breath sampling and the cor-
rect  interpretation  of  test  results.  These  preliminary
results  confirm  the  significant  difference  between
serum  kinetics  of  methacetin  and  the  kinetics  of
13Co2 in expired breath. Intravenous injection of 13C-
methacetin leads to a very early maximum of doB
values within less than 10 minutes, while the substrate
levels  have  already  decreased  significantly  from  its
maxima directly after injection. This could be inter-
preted  that  the  physiological  metabolism  of  13C-la-
beled methacetin is extremely fast at the administered
dosages.  Moreover  the  13Co2 excretion  and  thus
breath recovery appears to be significantly delayed in
comparison to the continuously rapid decrease of the
substrate serum levels. The prolonged pulmonary ex-
cretion of 13Co2 over one hour strongly confirms that
the quickly produced 13Co2 is not completely expired,
but a certain magnitude is stored as bicarbonate inside
different body compartments. as the  13C-methacetin
breath test was meant to analyze cytochrome capacity
and not individual bicarbonate kinetics, this phenome-
non  needs  to  be  considered  more  thoroughly.  as  a
consequence,  protocols  that  determine  test  readouts
from single time point breath samples could be signifi-
cantly influenced by individual bicarbonate kinetics. In
contrast, the online assessment analyzes a large num-
ber of breath samples – without any sampling bags or
tubes – and thus could also determine the individual
bicarbonate  kinetics.  as  a  result,  the  maximum  of
13Co2 excretion  can  be  accurately  determined  at  an
early point after injection and might be more closely
connected to the fast in vivo methacetin metabolism
(fig. 1). nevertheless, these effects need to be further
investigated  and  confirmed  in  larger  numbers  of
healthy volunteers and liver diseased patients. In con-
clusion, accurate test results from nBTs could only be
obtained, when other influencing factors such as the
physiological serum kinetics of the substrate and the
bicarbonate kinetics are taken into account in the de-
velopment of suitable test protocols.
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